Amgen Deal Struck As Tide Turns To Looser Off-Label Limits
Amgen Inc.'s $71 million multistate deal for off-label promotion follows a familiar pattern of settlements with states for a fraction of an earlier federal deal, but attorneys say the recent Amarin...To view the full article, register now.
Already a subscriber? Click here to view full article